The State of the Art in the Diagnosis, Staging, Treatment and Prognosis of Gastrointestinal and Urogenital Malignancies

Dear Colleagues,

Gastrointestinal and urogenital cancers are a highly diverse group of diseases, which, due to the lack of multiple specific symptoms in their early stages, are one of the most common causes of death in the world. Despite the constant development of diagnostic and therapeutic methods, the number of cancers is constantly growing, and thus causes a huge physical, emotional and financial burden both for individuals and healthcare systems. Gastric cancer is one of the most common causes of cancer-related deaths worldwide, whereas prostate cancer is the second most common malignancy among men. The main reason for treatment failure in patients with gastric cancer is a late diagnosis, with many patients not presenting any symptoms in advanced stages. Moreover, the occurrence of chemoresistance and the presence of metastases are important factors leading to the death of oncological patients. Therefore, there is an urgent need to develop new diagnostic and prognostic alternatives, as well as innovative therapeutic approaches that would, on the one hand, allow for the early detection of cancer and, on the other hand, would predict the behavior of the cancer and the risk of recurrence of the disease.

We are pleased to invite you to submit articles related to the aim of this Special Issue, which includes, among others, issues regarding advances in biomarkers to determine cancer diagnostic, prognostic and therapeutic options in gastrointestinal cancers (esophageal cancer, gastric cancer, liver cancer, pancreatic cancer and colorectal cancer) and urogenital cancers (bladder cancer, kidney cancer, prostate cancer and testicular cancer).

In this Special Issue, we encourage authors to publish basic and clinical research manuscripts, and we will accept both original research and review articles.

We look forward to receiving your contributions.

Dr. Agnieszka Kulczyńska-Przybik
Dr. Sara Pączek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.